our positive stance on ERIS given 1) scheduled potential launches, 2) strong pipeline of patent expiration opportunities and 3) rapidly growing new-generation brands along with power brands in core therapies. ERIS's timely strategy of capacity expansion and higher contribution from chronic/sub-chronic products supported by insignificant regulatory risk, allows it to stand ahead in the industry. We have not factored any revenues and expenses from this JV. Maintain our BUY'...